$IMUX

IMMUNIC, INC.

Immunic is a late-stage biotechnology company developing oral therapies for neurologic and gastrointestinal diseases. It is headquartered in New York City, with its main operations in Gräfelfing near Munich, Germany. Its three main programs are vidofludimus calcium (IMU-838), in Phase 3 development for relapsing multiple sclerosis; IMU-856, a small molecule targeting intestinal barrier function and bowel epithelium regeneration; and IMU-381, a program of next-generation molecules in preclinical testing for neurologic, gastrointestinal and other autoimmune diseases. Through its wholly owned subsidiary Gliomic Therapeutics, Immunic also pursues compounds for brain cancers. Immunic’s work centers on research and development of its drug candidates, which it aims to develop for potential regulatory approval and commercialization. It has no products approved for commercial sale and has not generated revenue from product sales. The company conducts research and development in Germany and Australia, including through a subsidiary in Melbourne, and had 92 employees as of February 1, 2026.

1
3
11

No SEC Form 4 filings for $IMUX in the last 30 days.

See all $IMUX insider activity →
Low

Small cap wrap: Gunnison Copper, Snail Games, Digi Power X

VivoPower (VIVO) launched an electric pickup for fleet use. U.S. Global Investors (GROW) reported 18% revenue growth. Digi Power X (DGXX) saw 50% revenue increase driven by AI. Snail (SNAL) turned profitable. Ocean Power (OPTT) priced a $3M stock offering. Gunnison Copper (GUNN) reported $36.1M revenue. Immunic (IMUX) expects Phase 3 trial data in December. Sigma Lithium (SGML) generated $24.2M cash flow. Caledonia (CMCL) discussed gold production. Amaroq Minerals (AMRQ) raised EBITDA forecast.

Immunic Q3FY26 Results: EPS of $(0.99) misses estimate, loss narrows 25% YoY

Immunic Inc reported a Q3FY26 EPS loss of $(0.99), missing estimates by $(0.03) but narrowing losses by 25% YoY. Operating expenses rose 65% to $42.3M, with R&D and G&A costs increasing. The company expects Phase 3 ENSURE trial data in December 2026 and has $132M in cash to fund operations into late 2027.

Immunic CEO discusses Q3 highlights and December Phase 3 MS trial readouts

Immunic Inc (IMUX) CEO Erik Lundgren discussed Q3 2026 performance, upcoming Phase 3 MS trial results in December, and plans for a progressive MS trial. Positive results could lead to an NDA submission in mid-2027. The company has $132M in cash and potential for $200M from warrants.

IMUX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 15 news stories mentioning IMUX (IMMUNIC, INC.). Coverage has skewed bearish: 1 bullish, 3 neutral, and 11 bearish.

Recent IMUX coverage spans financial news and earnings.

What's driving IMUX

  • Progress in late‑stage trial sustains biotech valuation.

    proactiveinvestors.com · Nov 13, 2026

  • Immunic Inc reported a Q3FY26 EPS loss of $(0.99), missing estimates by $(0.03) but narrowing losses by 25% YoY. Operating expenses rose 65% to $42.3M, with R&D and G&A costs increasing. The company expects Phase 3 ENSURE trial data in December 2026 and has $132M in cash to fund operations into late 2027.

    scanx.trade · Nov 13, 2026

  • The upcoming readout could drive significant price movement depending on trial outcomes.

    proactiveinvestors.com · Nov 13, 2026

  • The missed primary endpoint raises concerns, though modest disability signals may limit downside.

    finance.yahoo.com · Nov 6, 2026

  • The announcement adds a new catalyst for Immunic, likely generating modest buying interest ahead of the trial start.

    prnewswire.com · Oct 29, 2026

AlphAI scores every news story that mentions IMUX with an AI model for sentiment and relevance, and aggregates insider trades from IMMUNIC, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $IMUX

Score

Small cap wrap: Gunnison Copper, Snail Games, Digi Power X

VivoPower (VIVO) launched an electric pickup for fleet use. U.S. Global Investors (GROW) reported 18% revenue growth. Digi Power X (DGXX) saw 50% revenue increase driven by AI. Snail (SNAL) turned profitable. Ocean Power (OPTT) priced a $3M stock offering. Gunnison Copper (GUNN) reported $36.1M revenue. Immunic (IMUX) expects Phase 3 trial data in December. Sigma Lithium (SGML) generated $24.2M cash flow. Caledonia (CMCL) discussed gold production. Amaroq Minerals (AMRQ) raised EBITDA forecast.

$IMUXMedAI 8/10

Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting

Immunic, Inc. (IMUX) presented new data on vidofludimus calcium at MSToronto2026. Phase 2 CALLIPER trial data showed durable disability outcomes and consistent safety. Preclinical data suggested neuroprotective effects. Exploratory analyses linked reduced EBV-specific T-cell signatures to improved cognitive performance. A novel disability measure suggested overall benefits in progressive MS patients. The company plans to initiate a Phase 3 program in progressive MS later this year.

$IMUXMedAI 8/10

Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting

Immunic (IMUX) will present new data on vidofludimus calcium (IMU-838) at MSToronto2026. Four abstracts cover long-term disability outcomes, EBV-related immune activity, cognition, and novel disability measurement. Phase 2 CALLIPER trial data show favorable disability outcomes with continuous treatment. Immunic aims to showcase vidofludimus calcium's potential in multiple sclerosis.

Related tickers